CDKN1A and cancer: Overall, the NRF2-p21-p53 pathway contributes to resistance by enhancing antioxidant defenses, promoting drug efflux, and modulating DNA repair processes, thereby supporting cancer cell survival and reducing the efficacy of anticancer drugs like topoisomerase inhibitors and taxanes [128].